JnJ seeks USFDA approval for Simponi to treat pediatric ulcerative colitis
Horhsam: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of SIMPONI (golimumab) for the treatment of children two years and …